Trials / Conditions / Moderate Hepatic Impairment

Moderate Hepatic Impairment

10 registered clinical trials studyying Moderate Hepatic Impairment — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate H NCT07343960	AstraZeneca	Phase 1
Recruiting	Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) NCT06962332	Exelixis	Phase 1
Completed	A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Heal NCT05610657	Agios Pharmaceuticals, Inc.	Phase 1
Completed	A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020) NCT04995484	Merck Sharp & Dohme LLC	Phase 1
Completed	A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction NCT05224609	Pfizer	Phase 1
Completed	Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients NCT05116826	Genfit	Phase 1
Completed	Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment NCT04534699	KBP Biosciences	Phase 1
Completed	Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants NCT04223635	Daiichi Sankyo	EARLY_Phase 1
Completed	A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in H NCT02871570	GlycoMimetics Incorporated	Phase 1
Completed	A Study of TMC207 in Patients With Moderately Impaired Hepatic Function NCT01012284	Tibotec BVBA	Phase 1